Coya Therapeutics Holds Annual Stockholders Meeting

Coya Therapeutics, Inc. ( (COYA) ) just unveiled an update.

On June 26, 2025, Coya Therapeutics, Inc. held its Annual Meeting of Stockholders where two main matters were voted on: the election of three Class III directors and the ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm. Howard Berman, Ph.D., Arun Swaminathan, Ph.D., and Ann Lee, Ph.D. were elected as directors, and the accounting firm’s appointment was ratified, reflecting continued confidence in the company’s leadership and financial oversight.

The most recent analyst rating on (COYA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Spark’s Take on COYA Stock

According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.

Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.

To see Spark’s full report on COYA stock, click here.

More about Coya Therapeutics, Inc.

Average Trading Volume: 57,512

Technical Sentiment Signal: Sell

See more data about COYA stock on TipRanks’ Stock Analysis page.